Information Provided By:
Fly News Breaks for January 13, 2020
Jan 13, 2020 | 12:05 EDT
Piper Sandler analyst Danielle Brill maintained an Overwight rating and $42 price target on MorphoSys (MOR) after the company announced a global collaboration with Incyte (INCY) for the development of tafasitamab. Brill said the deal is "great" in terms of economics and future governance of the assets, though she does believe investors will question whether Incyte is the "ideal" partner to unlock tafasitamab's full potential. The analyst noted, however, that she does believe tafa will be a "top-priority" for both companies, and they will be equally committed to insuring it is a commercial success.
News For INCY;MOR From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.